-
IARC Monographs on the Evaluation of... 1996
Review
Topics: Animals; Anti-Anxiety Agents; Carcinogenicity Tests; Carcinogens; Humans; Temazepam
PubMed: 9097124
DOI: No ID Found -
Drug Intelligence & Clinical Pharmacy Sep 1982Temazepam is a benzodiazepine derivative indicated for the treatment of insomnia. Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to... (Review)
Review
Temazepam is a benzodiazepine derivative indicated for the treatment of insomnia. Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours. Sleep laboratory studies have demonstrated improvements in all sleep parameters except sleep onset latency. Clinically, patients report improvements in all sleep parameters including sleep onset latency. The efficacy of temazepam compares favorably with barbiturates, glutethimide, nitrazepam, lorazepam, oxazepam, and flurazepam. It has not been compared with diazepam in the clinical setting. Side effects include drowsiness, dizziness, and lethargy. The incidence of hangover effects from 15- and 30-mg doses is relatively low. Temazepam has no proven advantages over other benzodiazepine hypnotics. The major issues that need further clarification include temazepam's sleep induction properties and the relative incidence of hangover and rebound insomnia when compared with longer-acting benzodiazepines.
Topics: Animals; Anti-Anxiety Agents; Drug Interactions; Half-Life; Humans; Kinetics; Sleep Wake Disorders; Temazepam
PubMed: 6127197
DOI: 10.1177/106002808201600902 -
Nursing Times
Topics: Anti-Anxiety Agents; Humans; Patient Education as Topic; Temazepam
PubMed: 16617968
DOI: No ID Found -
Drugs May 1981Temazepam is a benzodiazepine drug which is a minor metabolite of diazepam. In clinical studies using subjective evaluation methods it was effective for maintaining... (Review)
Review
Temazepam is a benzodiazepine drug which is a minor metabolite of diazepam. In clinical studies using subjective evaluation methods it was effective for maintaining sleep and increasing total sleep time. However, sleep laboratory studies did not show a significant effect on some sleep parameters, especially sleep induction. Temazepam has a relatively short half-life (about 5 to 11 hours, longer in some subjects and in the elderly), and no active metabolites of clinical importance, and thus may be considered more suitable for use as an hypnotic than longer acting drugs such as diazepam, nitrazepam or flurazepam when residual sedative effects the next day are not desirable. Indeed, few residual effects on morning performance appear to occur with usual single doses of temazepam, although at the upper end of the recommended dosage range (30 mg or more) some evidence of impaired psychomoter and cognitive function in the morning has been reported. Whether or not temazepam is likely to produce "hangover" with repeated night-time administration needs further clarification. While a call for a large number of controlled trials may not be justifiable in evaluating a new hypnotic, a few well designed additional comparative studies in insomniac subjects are needed to assess adequately the relative merits of temazepam (particularly with regard to sleep onset) compared with other benzodiazepine hypnotics, especially those which are short- or intermediate-acting.
Topics: Animals; Anti-Anxiety Agents; Humans; Hypnotics and Sedatives; Kinetics; Temazepam
PubMed: 6112127
DOI: 10.2165/00003495-198121050-00001 -
Lancet (London, England) May 1988
Topics: Anti-Anxiety Agents; Capsules; Temazepam; Therapeutic Equivalency
PubMed: 2896948
DOI: No ID Found -
Lancet (London, England) Oct 1987
Topics: Anti-Anxiety Agents; Humans; Scotland; Substance-Related Disorders; Temazepam
PubMed: 2889020
DOI: 10.1016/s0140-6736(87)92539-6 -
Pharmacological Research 1993
-
British Dental Journal Nov 2000
Topics: Anti-Anxiety Agents; Drug Overdose; Female; Humans; Suicide, Attempted; Temazepam
PubMed: 11104086
DOI: No ID Found -
BMJ (Clinical Research Ed.) Nov 1988
Topics: Adult; Anti-Anxiety Agents; Dosage Forms; Female; Humans; Injections, Intravenous; Pregnancy; Substance-Related Disorders; Temazepam
PubMed: 2905899
DOI: 10.1136/bmj.297.6660.1402-a -
British Dental Journal Jul 2010
Topics: Anesthesia, Dental; Clinical Competence; Conscious Sedation; Humans; Hypnotics and Sedatives; Practice Patterns, Dentists'; Premedication; Temazepam
PubMed: 20651750
DOI: 10.1038/sj.bdj.2010.630